LinkBack URL
About LinkBacks
Reply With QuoteI've been buying CVM from Dec 08 through Aug 09.Never going to sell til Multikine comes to market.
Completion of Cel-Sci's New Facility Signals That Long Awaited Phase III Trial is Imminent
TD Ameritrade
I've been buying CVM from Dec 08 through Aug 09.Never going to sell til Multikine comes to market.
It looks like EUA (Emergency Use Authorization) may still happen.
Vienna, Virginia, Oct. 28, 2009 -- In a rare move, the FDA granted this pioneering company CEL-SCI a special expedited review of their novel H1N1 treatment. The approval process that usually takes years has been given the green light to occur much more rapidly. This decision comes amid recent rising concern about the nature and aggressiveness of the H1N1 virus. Vienna, Virginia-based CEL-SCI Corp. is currently spearheading the movement toward successfully treating the sickest patients who are in danger of dying from this disease.
PharmaLive: U.S. FDA Grants Rare Expedited Review Of CEL-SCI Corporation's New H1N1 Treatment
Is this the same news reported in Sept?Originally Posted by stockman
Wednesday, 16 September 2009 04:50
The U.S. Food and Drug Administration (FDA) has indicated that the Company can proceed with its first clinical trial to evaluate the effect of its investigational LEAPS-H1N1 treatment on the white blood cells of hospitalized H1N1 patients. This followed the very responsive and expedited initial review of CEL-SCI's regulatory submission for this study proposal. Following completion of manufacturing, initiation of this first study is subject to IRB review and approval.
In order for FDA to fully consider a next-stage clinical trial to evaluate LEAPS-H1N1 treatment of hospitalized patients with laboratory-confirmed H1N1 Pandemic Flu under an Exploratory IND, FDA has asked CEL-SCI to submit a detailed follow-up regulatory filing with extensive additional data.
Vienna, Virginia, Oct. 28, 2009
CEL-SCI is now able to press forward with human clinical trials to harness the power of their novel L.E.A.P.S. (Ligand Epitope Antigen Presentation System) technology for treating the H1N1 virus
Last edited by stockman; 11-02-2009 at 11:47 PM.
CEL-SCI to Conduct First Clinical Study of Investigational LEAPS-H1N1 Treatment for Hospitalized H1N1 Infected Patients at Johns Hopkins University School of Medicine
TD Ameritrade
I came across CVM about 5 months ago and it has good potential but it is a violatal stock. Be careful because it can pullback at anytime.
And it can take off at any time
CEL-SCI Collaborators Present Data Suggesting That LEAPS Technology Has Ability to Modify Immune Response
TD Ameritrade
anyone see any kind of timeline how logn these trials are expected to last and/or when they would offically start?
Posting Permissions 